Condition
CD30+ Peripheral T-cell Lymphoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
Trial Status
Withdrawn1
Not Yet Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07074457Not ApplicableRecruitingPrimary
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NCT07048353Early Phase 1Not Yet Recruiting
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT03205891Phase 1Withdrawn
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
Showing all 3 trials